Longitudinal model–based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer

被引：0
|
作者：
Wenjun Chen
Liang Li
Shuangmin Ji
Xuyang Song
Wei Lu
Tianyan Zhou
机构：
[1] Peking University,Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences
[2] National Medical Products Administration,Center for Drug Evaluation
[3] University of Florida,Department of Pharmaceutics, College of Pharmacy
来源：
European Journal of Clinical Pharmacology | 2020年 / 76卷
关键词：
Model-based meta-analysis; Castration-resistant prostate cancer; Progression-free survival; Overall survival; Longitudinal data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：589 / 601
页数：12
相关论文
共 50 条
  • [21] Enzalutamide for patients with metastatic castration-resistant prostate cancer
    Ramadan, Wijdan H.
    Kabbara, Wissam K.
    Al Masri, Hiba S. Al Basiouni
    ONCOTARGETS AND THERAPY, 2015, 8 : 871 - 876
  • [22] Risk stratification of castration-resistant prostate cancer patients treated with cabazitaxel
    Kosaka, Takeo
    Hongo, Hiroshi
    Mizuno, Ryuichi
    Oya, Mototsugu
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (06) : 683 - 688
  • [23] Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer
    Buettner, Thomas
    Kluemper, Niklas
    Weiten, Richard
    Lossin, Philipp
    Latz, Stefan
    Jacobs, Carolin
    Ritter, Manuel
    Hauser, Stefan
    Ellinger, Joerg
    Krausewitz, Philipp
    PROSTATE, 2024, 84 (12) : 1119 - 1127
  • [24] RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
    Boerrigter, Emmy
    Benoist, Guillemette E.
    van Oort, Inge M.
    Verhaegh, Gerald W.
    de Haan, Anton F. J.
    van Hooij, Onno
    Groen, Levi
    Smit, Frank
    Oving, Irma M.
    de Mol, Pieter
    Smilde, Tineke J.
    Somford, Diederik M.
    Hamberg, Paul
    Dezentje, Vincent O.
    Mehra, Niven
    van Erp, Nielka P.
    Schalken, Jack A.
    CANCERS, 2021, 13 (24)
  • [25] Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
    Sonpavde, Guru
    Pond, Gregory R.
    Templeton, Arnoud J.
    Fandi, Abderrahim
    Tombal, Bertrand
    Rosenthal, Mark
    Armstrong, Andrew J.
    Petrylak, Daniel P.
    EUROPEAN UROLOGY, 2016, 69 (06) : 980 - 983
  • [26] Immunotherapy for Castration-Resistant Prostate Cancer
    Sonpavde, Guru
    Kantoff, Philip W.
    UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : 465 - +
  • [27] Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials
    R Iacovelli
    A Altavilla
    G Procopio
    S Bracarda
    M Santoni
    S Cascinu
    E Cortesi
    Prostate Cancer and Prostatic Diseases, 2013, 16 : 323 - 327
  • [28] Diethylstilbestrol in castration-resistant prostate cancer
    Wilkins, Anna
    Shahidi, Mehdi
    Parker, Chris
    Gunapala, Ranga
    Thomas, Karen
    Huddart, Robert
    Horwich, Alan
    Dearnaley, David
    BJU INTERNATIONAL, 2012, 110 (11B) : E727 - E735
  • [29] Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials
    Iacovelli, R.
    Altavilla, A.
    Procopio, G.
    Bracarda, S.
    Santoni, M.
    Cascinu, S.
    Cortesi, E.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (04) : 323 - 327
  • [30] Efficacy and Toxicity of Anti-VEGF Agents in Patients with Castration-Resistant Prostate Cancer: a Meta-analysis of Prospective Clinical Studies
    Qi, Wei-Xiang
    Fu, Shen
    Zhang, Qing
    Guo, Xiao-Mao
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (19) : 8177 - 8182
12345